Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02969837
Title Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago

myeloid neoplasm


Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.